Small cell lung cancer is characterized by early metastases and rapid growth. While initially very responsive to both chemotherapy and radiation therapy, the majority of patients will have recurrent disease or become refractory to treatment. The 5-year survival of patients with small cell lung...
small-cell lung canceretiologypathophysiologydrug therapiesclinical trialsThe etiology and pathophysiology of small-cell lung cancer are described, followed by a detailed survey of current and emerging drug therapies. Keywords: small-cell lung cancer; etiology; pathophysiology; drug therapies; clinical ...
Small cell lung cancer (SCLC) represents 15% of lung cancers and is characterized by early dissemination, development of chemoresistance and a poor prognosis. A host of diverse drugs failed invariably and its mechanisms of global chemoresistance have not been characterized so far. SCLC represents the...
Small cell lung cancer (SCLC) is the most aggressive histologic subtype of lung cancer and accounts for roughly 13–15% of all lung cancers [1]. The recalcitrant nature of SCLC is demonstrated by rapid disease progression accompanied with early metastatic manifestation [2]. More than two-thirds...
Lineage-defining transcription factors (LTFs) play key roles in small-cell lung cancer (SCLC) pathophysiology. Delineating the LTF-regulated genes operative in SCLC could provide a road map to identify SCLC dependencies. We integrated chromatin landscape and transcriptome analyses of patient-derived SCLC...
cell lymphoma, neuroblastoma, and non-small cell lung cancer are a few examples of cancers in which the anaplastic lymphoma kinase (ALK) gene may be altered. When activated in cancer, the cancer cells may develop and proliferate due to these ALK gene alterations. Gene fusions, chromosomal ...
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
Small-Cell Lung Cancer Small-cell lung cancer (SCLC) is the most aggressive type of lung cancer, characterized by a rapid doubling time.1 This form of lung cancer is most frequently diagnosed in patients who have a history of heavy smoking.2 SCLC accounts for about 13% to 15% of all ne...
Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell lung cancer (NSCLC) constitutes around 85% of all lung cancer cases. Recently, the emergence of targeted therapy and immunotherapy revolutionized the treatment o
High PFKFB3 expression in cancer stem cells promotes glycolysis and survival in the tumor microenvironment. Inhibition of PFKFB3 by the glycolytic inhibitor PFK158 and by shRNA stable knockdown in small cell lung carcinoma (SCLC) cell lines inhibited glycolysis, proliferation, spheroid formation, and...